Aclaris Therapeutics (ACRS) EBIT: 2017-2025
Historic EBIT for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to -$17.1 million.
- Aclaris Therapeutics' EBIT fell 63.78% to -$17.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$153.3 million, marking a year-over-year decrease of 231.11%. This contributed to the annual value of -$141.9 million for FY2024, which is 45.79% down from last year.
- Aclaris Therapeutics' EBIT amounted to -$17.1 million in Q3 2025, which was up 6.84% from -$18.4 million recorded in Q2 2025.
- Over the past 5 years, Aclaris Therapeutics' EBIT peaked at -$4.0 million during Q4 2023, and registered a low of -$99.7 million during Q4 2024.
- In the last 3 years, Aclaris Therapeutics' EBIT had a median value of -$18.4 million in 2025 and averaged -$26.6 million.
- Its EBIT has fluctuated over the past 5 years, first soared by 86.08% in 2023, then crashed by 2,362.94% in 2024.
- Quarterly analysis of 5 years shows Aclaris Therapeutics' EBIT stood at -$22.9 million in 2021, then declined by 27.02% to -$29.1 million in 2022, then soared by 86.08% to -$4.0 million in 2023, then slumped by 2,362.94% to -$99.7 million in 2024, then plummeted by 63.78% to -$17.1 million in 2025.
- Its last three reported values are -$17.1 million in Q3 2025, -$18.4 million for Q2 2025, and -$18.1 million during Q1 2025.